No Benefit of Intermediate- vs Standard-Dose Prophylactic Anticoagulation Among Patients With COVID-19
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA: The Journal of the American Medical Association
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial
JAMA 2021 Apr 27;325(16)1620-1630, P Sadeghipour, AH Talasaz, F Rashidi, B Sharif-Kashani, MT Beigmohammadi, M Farrokhpour, SH Sezavar, P Payandemehr, A Dabbagh, KG Moghadam, S Jamalkhani, H Khalili, M Yadollahzadeh, T Riahi, P Rezaeifar, O Tahamtan, S Matin, A Abedini, S Lookzadeh, H Rahmani, E Zoghi, K Mohammadi, P Sadeghipour, H Abri, S Tabrizi, SM Mousavian, S Shahmirzaei, H Bakhshandeh, A Amin, F Rafiee, E Baghizadeh, B Mohebbi, SE Parhizgar, R Aliannejad, V Eslami, A Kashefizadeh, H Kakavand, SH Hosseini, S Shafaghi, SF Ghazi, A Najafi, D Jimenez, A Gupta, MV Madhavan, SS Sethi, SA Parikh, M Monreal, N Hadavand, A Hajighasemi, M Maleki, S Sadeghian, G Piazza, AJ Kirtane, BW Van Tassell, PP Dobesh, GW Stone, GYH Lip, HM Krumholz, SZ Goldhaber, B BikdeliFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.